Nifedipine Treatment on Uterine Contractility in IVF
Last updated on April 2022Recruitment
- Recruitment Status
- Unknown status
Inclusion Criteria
- Patient undergoing frozen embryo transfer
- Patient undergoing frozen embryo transfer
Exclusion Criteria
- Unwillingness to give written informed consent. Previous entry into this study or simultaneous participation in another clinical trial.
- Body mass index (BMI) > 38 kg/m2
- Administration of any investigational drugs within three months prior to study enrollment.
- ...
- Unwillingness to give written informed consent. Previous entry into this study or simultaneous participation in another clinical trial.
- Body mass index (BMI) > 38 kg/m2
- Administration of any investigational drugs within three months prior to study enrollment.
- Any contraindication to being pregnant and carrying a pregnancy to term.
- Patient treating with other drugs that interact with cytochrome P450 activity: azole antifungals, cimetidine, cyclosporine, erythromycin, quinidine, terfenadine, warfarin, benzodiazepines, flecainide, imipramine, propafenone and theophylline.
- Contraindication for the use of nifedipine, Estrogen and Progesterone suppositories.
- Patient not able to communicate adequately with the investigators and to comply with the requirements of the entire study.
- Abnormal uterine cavity as evidenced by sonohysterogram or hysterosalpingography
- Any ovarian or abdominal abnormality that may interfere with adequate transvaginal sonography (TVS) evaluation.
- Irregular heart beat or already being treated with another medication for high blood pressure.
- Early follicular phase (day 2-4) serum follicle stimulating hormone (FSH) level > 20 mIU/ml.
Summary
- Conditions
- Embryo Implantation
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 45 years
- Gender
- Only females
Inclusion Criteria
- Patient undergoing frozen embryo transfer
- Patient undergoing frozen embryo transfer
Exclusion Criteria
- Unwillingness to give written informed consent. Previous entry into this study or simultaneous participation in another clinical trial.
- Body mass index (BMI) > 38 kg/m2
- Administration of any investigational drugs within three months prior to study enrollment.
- ...
- Unwillingness to give written informed consent. Previous entry into this study or simultaneous participation in another clinical trial.
- Body mass index (BMI) > 38 kg/m2
- Administration of any investigational drugs within three months prior to study enrollment.
- Any contraindication to being pregnant and carrying a pregnancy to term.
- Patient treating with other drugs that interact with cytochrome P450 activity: azole antifungals, cimetidine, cyclosporine, erythromycin, quinidine, terfenadine, warfarin, benzodiazepines, flecainide, imipramine, propafenone and theophylline.
- Contraindication for the use of nifedipine, Estrogen and Progesterone suppositories.
- Patient not able to communicate adequately with the investigators and to comply with the requirements of the entire study.
- Abnormal uterine cavity as evidenced by sonohysterogram or hysterosalpingography
- Any ovarian or abdominal abnormality that may interfere with adequate transvaginal sonography (TVS) evaluation.
- Irregular heart beat or already being treated with another medication for high blood pressure.
- Early follicular phase (day 2-4) serum follicle stimulating hormone (FSH) level > 20 mIU/ml.
Tracking Information
- NCT #
- NCT02072291
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Assaf Ben-Meir, MD Hadassah Medical Center
- Assaf Ben-Meir, MD Hadassah Medical Center
Get Well Soon